Related Experiment Videos
Systemic candidiasis in premature infants experience with drug treatment
Annals of the Academy of Medicine, Singapore
|October 1, 1985
Abstract:
Eleven premature infants with systemic candidiasis from 1981 to 1984 have been reported previously. The experience with antifungal drugs is presented. Amphotericin B at lower maintenance dose, together with 5 flucytosine (5FC), are the preferred drugs for treatment of systemic candidiasis at present.
Insights
Systemic candidiasis in premature infants requires effective antifungal treatment. Amphotericin B at a lower dose combined with 5-flucytosine (5FC) is currently the preferred therapeutic approach.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Pharmacology
Background:
- Systemic candidiasis poses a significant threat to premature infants.
- Previous reports documented eleven cases between 1981 and 1984.
Purpose of the Study:
- To present the clinical experience with antifungal drug therapy for systemic candidiasis in premature neonates.
- To identify preferred antifungal agents for treating invasive fungal infections in this vulnerable population.
Main Methods:
- Review of clinical data for eleven premature infants diagnosed with systemic candidiasis.
- Analysis of antifungal drug regimens utilized, focusing on Amphotericin B and 5-flucytosine (5FC).
Main Results:
- Experience with various antifungal drugs was evaluated.
- Amphotericin B, when administered at a reduced maintenance dosage, demonstrated efficacy.
Conclusions:
- A combination of lower-dose Amphotericin B and 5-flucytosine (5FC) is recommended as the current standard of care for treating systemic candidiasis in premature infants.